...
首页> 外文期刊>Current pharmaceutical design >Therapeutic application of intrabodies against age-related neurodegenerative disorders.
【24h】

Therapeutic application of intrabodies against age-related neurodegenerative disorders.

机译:体内治疗针对年龄相关性神经退行性疾病的应用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Many neurodegenerative diseases, referred to as misfolding diseases, are characterized by the formation and accumulation of pathological extracellular and intracellular misfolded aggregates. Ageing is considered the major risk factor for neurodegenerative disorders and, due to increase of mean lifespan, the clinical relevance is growing dramatically with a urgent need to find new effective therapeutic approaches. The intracellular antibody technology is a gene-based strategy which exploits the specificity of recombinant antibodies to neutralize or modify the function of intracellular and extracellular target antigens. Intrabodies can potentially recognize all the pathological conformers of a misfolding-prone protein, and therefore they are emerging as therapeutic agents for the treatment of misfolding diseases as well as molecular tools for the understanding of their pathogenesis. Here we focus on the application of intrabodies against two major age-related neurodegenerative disorders, Alzheimer's disease (AD) and Parkinson's disease (PD) and the description of in vivo gene delivery systems available for their potential entering in the clinical setting.
机译:许多神经退行性疾病,称为错误折叠疾病,其特征是病理性细胞外和细胞内错误折叠聚集体的形成和积累。衰老被认为是神经退行性疾病的主要危险因素,由于平均寿命的延长,临床相关性正在急剧增长,迫切需要寻找新的有效治疗方法。细胞内抗体技术是一种基于基因的策略,它利用重组抗体的特异性来中和或修饰细胞内和细胞外靶抗原的功能。体内抗体可以潜在地识别易错折叠蛋白的所有病理构象异构体,因此它们正逐渐成为治疗错折叠疾病的治疗剂以及用于理解其发病机理的分子工具。在这里,我们专注于针对两种主要的与年龄相关的神经退行性疾病阿尔茨海默氏病(AD)和帕金森氏病(PD)的体内抗体的应用,以及体内基因传递系统的描述,因为它们有可能进入临床环境。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号